iCell Cardiomyocytes, 11713

Kit Size

Catalog #: R1105
Catalog #: R1117
Catalog #: R1106

Cells Only

Catalog #: C1105
Catalog #: C1106
Catalog #: C1106

Cardiomyocytes differentiated from human iPS cells, frozen

From
$595.00
Catalog # GCMC11713

Product Overview

Heart disease encompasses a wide range of conditions that can be a result of genetics, physiologic, and metabolic disorders as well as adverse drug reactions. The availability of human cell models that could be used to interrogate these various factors would have a profound impact on the effort to find new medicines and cures for heart disease. Derived from induced pluripotent stem cells (iPSCs), iCell® Cardiomyocytes from FUJIFILM Cellular Dynamics, Inc. (FCDI), enable a wide range of applications spanning disease research, drug discovery, safety and toxicity testing, and regenerative medicine.

  • Industry Standard With the most peer-reviewed publications and supported application protocols, iCell Cardiomyocytes are the in vitro model of choice.
  • Reproducible Research High purity and rigorous quality control ensure the same performance and reproducible results with every batch of iCell Cardiomyocytes.
  • Human Relevance iCell Cardiomyocytes recapitulate healthy human cardiac biology and function and express relevant targets and pathways for heart disease research.
  • Diverse Availability iCell Cardiomyocytes are now available from two backgrounds with no known disease-related genotypes: donors 01434 and 11713. Also available are cardiomyocytes generated from diseased backgrounds and engineered genotypes, including MyCell® Cardiomyocytes (R403Q), a model of hypertrophic cardiomyopathy derived from donor 01178 with genotype MYH7 R403Q.

Components:

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Technical Docs

PROTOCOLS

Performance Data

iCell Cardiomyocytes are a High-Purity Cardiac Population.

Flow cytometry analysis and immunostaining show that iCell Cardiomyocytes are typically >95% cTNT+) with intact sarcomeric myofilament organization. (Data were adapted from Kattman et al., 2011).

Figure 1: iCell Cardiomyocytes are a High-Purity Cardiac Population.

Figure 2: iCell Cardiomyocytes Recapitulate Native Cardiac Function

iCell Cardiomyocytes Recapitulate Native Cardiac Function

iCell Cardiomyocytes form a spontaneously beating monolayer within 7 days. iCell Cardiomyocytes contain the expected human cardiac ionic currents and show the expected effects when exposed to compounds including ion channel blockers. (Data were adapted from Ma et al., 2011).

 iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling.

Their electrophysiological activity can be pharmacologically modulated and quantified by recording the electrical activity using a multielectrode array (MEA). The field potential duration (FPD) increases or decreases as expected when exposed to ion channel-blocking drugs for key cardiac channels.

Figure 3:  iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling.

Figure 4: Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity.

Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity.

Electrical activity at the membrane is controlled by ion channels and GPCRs. This activity drives intracellular Ca2+ handling. Panel A shows representative calcium handling waveforms at baseline. Panels B and C show the effect of the GPCR β-adrenergic agonist ISO or the IKr channel blocker E-4031, respectively.

Product Highlights

Regenerative Medicine

iCell Cardiomyocytes are compatible with bioengineered, implantable scaffolds used as a model for heart repair following myocardial infarction (Richards et al., 2017, Beauchamp et al., 2015, Holt-Casper et al., 2015, Lancaster et al., 2012).

Calcium Signaling

Simultaneously assess effects on electrical and calcium signals measurements using iCell Cardiomyocytes with FDSS ( Bedut et al., 2016) or FLIPR platforms.

Cardiac Hypertrophy Studies

iCell Cardiomyocytes can detect known and novel biomarkers and identify new targets for drug discovery and therapeutics research (Jones et al., 2015, Drawnel et al., 2014, Arrarwal et al., 2014, Traister et al., 2014, Zhi et al., 2012).

Arrhythmia Testing

iCell Cardiomyocytes are changing regulatory paradigms by providing a highly predictive model for detecting drug-induced arrhythmia (Guo et al., 2018).

Cardiotoxicity Assessment

Retrospective analyses were leveraged to uncover previously undetected mechanisms of drug-induced cardiotoxicity and provide relevant data in support of Investigational New Drug (IND) applications (Talbert et al., 2014, Cameron et al., 2013, Doherty et al., 2013, Rana et al., 2012, Cohen et al., 2011).